Tuberculosis emerged as an epidemic in the 1600s, began to decline as sanitation improved in the 19th century, and retreated further when effective therapy was developed in the 1950s. TB was virtually forgotten until a recent resurgence in the U.S. and around the world—ominously, in forms resistant to commonly used medicines.
What must the nation do to eliminate TB? The distinguished committee from the Institute of Medicine offers recommendations in the key areas of epidemiology and prevention, diagnosis and treatment, funding and organization of public initiatives, and the U.S. role worldwide. The panel also focuses on how to mobilize policy makers and the public to effective action.
The book provides important background on the pathology of tuberculosis, its history and status in the U.S., and the public and private response.
The committee explains how the U.S. can act with both self-interest and humanitarianism in addressing the worldwide incidence of TB.
Institute of Medicine. 2000. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC: The National Academies Press. https://doi.org/10.17226/9837.
|1 Fundamentals of Tuberculosis and Tuberculosis Control||13-22|
|2 The Current Situation and How We Got Here||23-50|
|3 Tuberculosis Elimination and the Changing Role of Tuberculosis Control Programs||51-85|
|4 Advancing Toward Elimination||86-121|
|5 Developing the Tools for Tuberculosis Elimination||122-148|
|6 The U.S. Role in Global Tuberculosis Control||149-158|
|7 Mobilizing for Elimination||159-168|
|Appendix A Statement of Task||169-172|
|Appendix B Public Session Agendas||173-181|
|Appendix C Site Visit Summaries||182-204|
|Appendix D Role of Public Health Laboratories in the Control of Tuberculosis||205-233|
|Appendix E Estimating the Number of Tuberculosis Cases That Can Be Prevented by a Program of Screening and Preventive Therapy of Newly Arrived Immigrants to the United States from Countries with a High Rate of Tuberculosis a||234-243|
|Appendix F Approval Dates for Existing and Prospects for Development of New Antituberculosis Drugs and Vaccines||244-249|
|Appendix G Committee Biographies||250-256|
The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.